Scientific Online Resource System

Izvestia Journal of the Union of Scientists - Varna. Medicine and Ecology Series

Three-year experience in treating patients with severe ulcerative colitis with biosimilar Infliximab (RemsimaTM)

Asiyana Petrova, Miglena Stamboliyska, Maria Tzaneva, Pavlina Boykova

Abstract

Introduction: The biosimilar version of Infliximab (RemsimaTM) showed clinical efficiency and immunogenicity similar to Infliximab in the treatment of ulcerative colitis. In Bulgaria the treatment with biosimilar Infliximab (RemsimaTM) has been approved since July 2014.

Aim: We have set ourselves the goal of study to investigate the efficacy and safety of biosimilar Infliximab (RemsimaTM) in patients with severe ulcerative colitis.

Patients and Methods: Over of a period of three years in the Clinic of Gastroenterology, St. Marina University Hospital, Varna, Bulgaria, fifteen patients with severe ulcerative colitis were treated with Infliximab (RemsimaTM) including patients who received at least one infusion: both anti-TNF naïve and patients who switched from another anti-TNF. Efficiency criteria: clinical response, clinical remission, mucosal healing, serum C-reactive protein (CRP) levels were observed on week 6, 24 and 52.

Results and Discussion: All patients had an early clinical response at week 6 and very good improvement at week 24. The total Mayo Score was reduced to 9 points at week 24. The CRP level decreased in all patients. Twelve patients had clinical remission at week 24 (80%). After the treatment, the patients had improved quality of life.

Conclusion: Our primary results with biosimilar Infliximab (RemsimaTM) showed a very good efficiency in terms of achieving clinical remission in the induction period in the treatment of patients with severe ulcerative colitis. 


Keywords

ulcerative colitis; biosimilar; clinical response; remission

Full Text


References

Alan C. Moss Optimizing the use of biological therapy in patients with inflammatory bowel disease, Gastroenterology Report, 2015

Alice M. Lee, Rohan Mandaliyab, Mark C. Mattar, Induction of remission in moderate-to-severe steroid refractory ulcerative colitis using patient-driven non-pharmacologic therapy, Elsevier 2018

А. Атанасова, Хронични възпалителни заболявания на червата- поглед от XXI век(съвсременни аспекти), 2015

Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D. et al. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, The New England Journal of Medicine, 2013

Axel Dignass, Rami Eliakim1 et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Elsevier 2012

Edward V. Loftus Jr, MD, Highlights in Ulcerative Colitis and Crohn’s Disease From the 2018 DDW Meeting, Gastroenterology and Hepatology Journal, 2018

Fernando Magro, Paolo Gionchetti, Rami Eliakim et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Journal of Crohn's and Colitis, 2017

Giulia Roda, MD, PhD, Bindia Jharap, MD, PhD, et al. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management, Clinical and Translational Gastroenterology (2016)

Jean-Frédéric Colombel, Bruce E Sands et al., The safety of vedolizumab for ulcerative colitis and Crohn’s disease, Inflammatory bowel disease 2015

Jørgen Jahnsen, Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients, Therapeutic Advances in Gastroenterology

Juan Ricardo Márquez, Fernando GomollónThe Role of Biosimilars in Inflammatory Bowel Disease: A Reality in our Country, 2017 Asociaciones Colombianas de Gastroenterología, Endoscopia digestiva, Coloproctología y Hepatología

M. F. Guerra Veloz, F. Argüelles Arias and etc., Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment, Abstracts of the 11th Congress of ECCO - European Crohn’s and Colitis Organisation

Michael J. Rosen, Philip Minar and Alexander A. Vinks. Applying Pharmacokinetics to Optimize Dosing of Anti-TNF Biologics in Acute Severe Ulcerative Colitis. Aliment Pharmacol Ther., 2015

Paul Rutgeerts, M.D., Ph.D., William J. Sandborn, M.D. et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, The New England Journal of Medicine, 2005

ROLANDE. ANDERSSON, M.D., PH.D., GUNNAROLAISON, M.D., PH.D., APPENDECTOMY AND PROTECTION AGAINST ULCERATIVE COLITIS, The New England Journal of Medicine 2001

S. Danese*, J.-F. Colombel, L. Peyrin-Biroulet, P. Rutgeerts, W. Reinisch, Review article: the role of anti-TNF in the management of ulcerative colitis–past, present and future, , Alimentary Pharmacology and Therapeutics, 2013

Проф. д-р И. Коцев, Съвременна класификация и индекси за оценка на възпалителните чревни болести, Medinfo, 2015

Sophie E. Berends, Anne S. Strik et. al., Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis, Clin Pharmacokinet 2018

Saransh Jain, Vineet Ahuja, Jimmy K Limdi, Optimal management of acute severe ulcerative colitis, Postgrad Med Journal

Yamamoto et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clinical and Translational Gastroenterology, 2018




DOI: http://dx.doi.org/10.14748/isuvsme.v24i2.6198

Refbacks

Font Size


|